CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

Scribe's $96M IPO; Scholar Rock awaits site classification for apitegromab

IPO/OfferingapitegromabPositive
AI Analysis

Summary

Scribe Therapeutics priced its Nasdaq IPO at $14 per share, expecting net proceeds of approximately $96 million. Scholar Rock awaits site classification for apitegromab.

Importance:7/10
Sentiment:
0.50
IPOgene editingcapital raisingregulatory
Related Companies

Read the original article

Published by Endpoints News on July 20, 2026 3:20 PM

Read Original